ClinicalTrials.gg
Active, not recruitingNCT06336330EvolutionHF-DEUpdated Jul 13, 2026

Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in Germany

An observational study in Heart Diseases, Cardiovascular Diseases and Heart Failure, sponsored by AstraZeneca. Active, not recruiting at 47 sites in Germany. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-07-13.

Primary conditionHeart FailureRegistry: Heart DiseasesReclassifiedWhy we changed it
Registry
Heart Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Heart Failure
Why
  1. The study's listed conditions name Heart Failure, a narrower term within Heart Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by AstraZeneca · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
831
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Heart Failure by AstraZeneca — 5 open to participants now, 8 under way, 3 of them phase 3. Heart Failure · AstraZeneca.

Enrollment
11th of 25
831 · median 621
Started
2024
with 6 others
Observational
25 of 64
3 open now
Registered
56th of 64
by date

Among the 64 studies in Heart Failure by AstraZeneca, this one is the 11th largest by enrollment of the 25 observational ones that give a count, is one of 7 that started in 2024, is one of 25 observational ones, and was the 56th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

5 of the 64 studies in Heart Failure by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Heart Failure by AstraZeneca, or all of them as a file.
02

Study summary

Heart failure (HF) is a global, public health issue that affects more than 63 million people worldwide; this burden is expected to increase substantially as the population ages. Despite advancements in treatment, a HF diagnosis still leads to significant morbidity and mortality; there is also an immense impact on patients' health-related quality of life (HRQoL). Dapagliflozin was recently granted approval for heart failure by the European Commission, regardless of ejection fraction and whether the patient has diabetes. Real-world observational data are necessary to describe dapagliflozin use in real-world settings in order to assess treatment patterns, HF symptoms and their impact on physical limitation, HRQoL and work productivity, as well as health care utilization of patients treated with dapagliflozin in this setting under local treatment standard conditions in Germany.

03

Conditions studied

  • Heart Diseases
  • Cardiovascular Diseases
  • Heart Failure

Browse trials for

Keywords

  • Heart Failure with preserved ejection fraction (HFpEF)
  • Heart Failure with mildly reduced ejection fraction (HFmrEF)
  • Heart Failure with Reduced Ejection Fraction (HFrEF)
  • Dapagliflozin
  • Real-World
04

In context

Heart Failure Reclassified

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

This study's enrollment of 831 is above the median of 200 across 1,987 observational studies indexed under Heart Failure.

Browse Heart Failure studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 179 (49%) have results posted.

Compared within Heart Failure, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Heart Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who have received treatment with dapagliflozin for HF since 14-90 day before entering the study will be eligible for enrolment by either primary or secondary care healthcare professionals from outpatient settings. All treatment decisions (i.e., dose and duration of treatment) will be at the discretion of the patient's healthcare provider. Patients may have discontinued from dapagliflozin prior to enrolment onto the study, as long as their dapagliflozin initiation was ≥14 days and ≤90 days prior to enrolment onto the study. Data on other parameters may be obtained at the date of initiation of dapagliflozin by extracting this information retrospectively from medical charts. Patients will only be enrolled after they have given consent to participate in the study. It is at the discretion of the physician whether or not to initiate patients on treatment with dapagliflozin and enrol them in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years as of study index date; the study index date is date of initiation of treatment with dapagliflozin
  • Patient received/receiving treatment with dapagliflozin in accordance with the local dapagliflozin product label for symptomatic chronic heart failure (HF) and at timepoint of dapagliflozin initiation with:

    • preserved (HFpEF; EF≥50%) OR mildly reduced ejection fraction (HFmrEF; EF 41-49%)
    • OR reduced ejection fraction (HFrEF EF ≤40%)
  • Patient is enrolled within 14 to 90 days following initiation of dapagliflozin
  • Signed and dated prior to enrolment in the study

Exclusion criteria

Exclusion Criteria:

  • Patient should not be enrolled if he/she is less than 14 days or more than 90 days following initiation of dapagliflozin
  • Prior treatment with dapagliflozin or other SGLT2i treatment
  • Initiation of dapagliflozin outside of the local HF label
  • Diagnosis of Type 1 diabetes prior to enrolment
  • Current or planned participation in a clinical trial using an medical product for treating HF
  • Patient is involved in the planning and/or conduction of the study
  • to dapagliflozin or to any of the listed in the SmPC
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
831 participants (actual)
Patient registry
No

Groups and cohorts

  • HFpEF

    Adult patients with preserved ejection fraction (HFpEF; EF≥50%) who receive treatment with dapagliflozin in accordance with the local dapagliflozin product label for symptomatic chronic heart failure.

  • HFmrEF

    Adult patients with mildly reduced ejection fraction (HFmrEF; EF 41-49%) who receive treatment with dapagliflozin in accordance with the local dapagliflozin product label for symptomatic chronic heart failure.

  • HFrEF

    Adult patients with reduced ejection fraction (HFrEF; EF ≤40%) who receive treatment with dapagliflozin in accordance with the local dapagliflozin product label for symptomatic chronic heart failure.

07

What researchers measure

Primary outcomes

  1. Time to discontinuation of dapagliflozin

    Time from dapagliflozin treatment initiation until the time at which participants stop taking the medication for any reason (from the perspective of the prescriber).

    Time frame: Baseline to 12 months

  2. Reasons for discontinuation of dapagliflozin

    Reasons for discontinuation (from the perspective of the prescriber) of patients initiated on dapagliflozin for HF will be described.

    Time frame: Baseline to 12 months

  3. Dose changes of dapagliflozin

    The number of participants with doses changes for dapagliflozin

    Time frame: Baseline to 12 months

  4. Number of patients with dapagliflozin treatment interruptions

    The number of participants who discontinue treatment with dapagliflozin.

    Time frame: Baseline to 12 month

  5. Treatment switches from dapagliflozin to other SGLT2i

    The number of participants who switch from dapagliflozin to another SGLT2i (Sodium-glucose cotransporter-2 inhibitor) treatment for HF.

    Time frame: Baseline to 12 months

  6. Time to other heart failure treatment discontinuation

    Time from initiation of heart failure medication other than dapagliflozin until the time at which participants discontinued treatment with that medication.

    Time frame: Baseline to 12 months

  7. Number of other heart failure treatment initiation

    The number of participants who initiate new heart failure medication other than dapagliflozin.

    Time frame: Baseline to 12 months

  8. Number of other heart failure treatment dosage changes

    The number of participants with dosage changes for heart failure medication other than dapagliflozin.

    Time frame: Baseline to 12 months

  9. Number of other heart failure treatment discontinuation

    The number of participants who discontinue treatment with heart failure medication other than dapagliflozin.

    Time frame: Baseline to 12 months

  10. Number of glucose lowering medication initiation

    The number of participants who initiate new glucose lowering medication other than dapagliflozin.

    Time frame: Baseline to 12 months

  11. Number of glucose lowering medication dosage changes

    The number of participants with dosage changes for glucose lowering medication other than dapagliflozin.

    Time frame: Baseline to 12 months

  12. Number of glucose lowering medication discontinuation

    The number of participants who discontinue treatment with glucose lowering medication other than dapagliflozin.

    Time frame: Baseline to 12 months

Secondary outcomes

  1. Absolute change from baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) score

    The KCCQ is a 23-item questionnaire that quantifies physical limitations, self-efficacy, social interference and quality of life. Several summary scores may be calculated including: Total Symptom score (measuring symptom frequency and symptom burden), Physical limitation score (measuring limitations in common physical activities), Clinical Summary score (measure of physical limitations and total symptoms), and an Overall Summary score (measure of physical limitations, total symptoms, HRQoL, and social limitations). Summary scores will be examined at each assessment point during follow-up.

    Time frame: Measured at 3, 6, 9 and 12 months

  2. Absolute change from baseline in Medication Adherence Report Scale (MARS)-5 questionnaire

    The MARS-5 is five-item self-report adherence scale which assesses both intentional and non-intentional non-adherence. Respondents rate the frequency with which the five different medication-taking behaviours occur, scoring each item on a 1-5-point scale with higher scores indicating higher reported adherence. The MARS-5 has been shown to be reliable and valid across a variety of health conditions, including cardiovascular and pulmonary diseases.

    Time frame: Measured at 3, 6, 9 and 12 months

  3. Absolute change from baseline in Work Productivity and Activity Impairment (WPAI) score

    The WPAI is a validated instrument to measure impairments in paid and unpaid work and activities. It measures absenteeism (work time missed), presenteeism (impairment at work / reduced on-the-job effectiveness) as well as the impairments in unpaid activity because of health problems during the past seven days. It has been validated to quantify work impairments for numerous diseases such as asthma, psoriasis, irritable bowel syndrome, and Crohn's disease, but has not yet been validated for use in heart failure participants. Scores will be derived from the overall work impairment at each timepoint and then changes of from baseline will be reported.

    Time frame: Measured at 3, 6, 9 and 12 months

Other outcomes

  1. The absolute change from baseline in occurrence of depressions in patients initiated on dapagliflozin for HF as captured by the Patient Health Questionnaire-9 (PHQ-9)

    The PHQ-9 comprises 9 items that capture depressed mood and anhedonia. It has been validated as a screening tool with good evidence of responsiveness. The PHQ-9 score is obtained by adding the score for each question (total points). PHQ-9 score ≥10 showed a sensitivity of 88% and a specificity of 88% for major depression. PHQ-9 scores of 5, 10, 15, and 20 have been shown to represent mild, moderate, moderately severe, and severe depression, respectively.

    Time frame: Measured at 3, 6, 9 and 12 months

  2. Healthcare resource utilisation - Number of hospitalisations since dapagliflozin initiation

    The number of patients hospitalised will be examined at each assessment point.

    Time frame: Measured at 3, 6, 9 and 12 months

  3. Healthcare resource utilisation - Length of HF-related hospital stay since dapagliflozin initiation

    Duration of outpatient clinic visits in days, will be examined at each assessment point.

    Time frame: Measured at 3, 6, 9 and 12 months

08

Study locations

47 sites
  • Research Site
    Aachen, 52062, Germany
  • Research Site
    Alsfeld, 36304, Germany
  • Research Site
    Bamberg, 96049, Germany
  • Research Site
    Bechhofen, 66894, Germany
  • Research Site
    Bergisch Gladbach, 51465, Germany
  • Research Site
    Berlin, 12489, Germany
  • Research Site
    Berlin, 12555, Germany
  • Research Site
    Brilon, 59929, Germany
  • Research Site
    Bruchsal, 76646, Germany
  • Research Site
    Chemnitz, 09113, Germany
  • Research Site
    Dinslaken, 46535, Germany
  • Research Site
    Erfurt, 99084, Germany
  • Research Site
    Erfurt, 99097, Germany
  • Research Site
    Essen, 45128, Germany
  • Research Site
    Frankenthal, 67227, Germany
  • Research Site
    Gera, 07551, Germany
  • Research Site
    Hamburg, 20095, Germany
  • Research Site
    Hamburg, 22087, Germany
  • Research Site
    Hamburg, 22459, Germany
  • Research Site
    Hoppegarten, 15366, Germany
  • Research Site
    Kaiserslautern, 67655, Germany
  • Research Site
    Kitzingen, 97318, Germany
  • Research Site
    Ludwigsburg, 71634, Germany
  • Research Site
    Ludwigshafen am Rhein, 67071, Germany
  • Research Site
    M Hldorf, 84453, Germany
  • Research Site
    Markkleeberg, 4416, Germany
  • Research Site
    Meiningen, 98617, Germany
  • Research Site
    Münster, 48149, Germany
  • Research Site
    Naumburg, 6618, Germany
  • Research Site
    Nuremberg, 90402, Germany
  • Research Site
    Oschersleben, 39387, Germany
  • Research Site
    Papenburg, 26871, Germany
  • Research Site
    Pirna, 01796, Germany
  • Research Site
    Potsdam, 14471, Germany
  • Research Site
    Querfurt, 06268, Germany
  • Research Site
    Ratingen, 40882, Germany
  • Research Site
    Rostock, 18059, Germany
  • Research Site
    Schleswig, 24837, Germany
  • Research Site
    Schwandorf in Bayern, 92421, Germany
  • Research Site
    Schwäbisch Hall, 74523, Germany
  • Research Site
    Siegen, 57072, Germany
  • Research Site
    Steinfurt, 48565, Germany
  • Research Site
    Stollberg, 09366, Germany
  • Research Site
    Straubing, 94315, Germany
  • Research Site
    Stuttgart, 70178, Germany
  • Research Site
    Ulm, 89073, Germany
  • Research Site
    Wermsdorf, 04779, Germany
09

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Dec 2026, 32 months after the start.

Of 183 industry-sponsored observational studies under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 57. This study's planned 32 months is close to that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2024
First posted
Mar 28, 2024
StartActual
Apr 25, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06336330
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 28, 2024
Start date
Apr 25, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion